WebDoctor Encyclopedia

Gynecologic Uterine

Uterine carcinosarcoma (malignant mixed Mullerian tumour)

Uterine carcinosarcoma is an aggressive womb cancer made of both carcinoma and sarcoma cells, now classed as a high-grade endometrial cancer. It mainly affects older women, often presents with bleeding after the menopause, and is treated with surgery and chemotherapy.

Medically reviewed Last reviewed October 21, 2026

What is uterine carcinosarcoma?

Uterine carcinosarcoma (UCS) is a rare, high-grade cancer of the womb (uterus). It contains two kinds of cancer cell mixed together: a carcinoma part, which looks like cancer of the womb lining, and a sarcoma part, which looks like cancer of connective tissue such as muscle, cartilage or bone.

It used to be called malignant mixed Mullerian tumour (MMMT). It was once grouped with the uterine sarcomas, but research has shown that the sarcoma part grows out of the carcinoma part. For this reason doctors now treat carcinosarcoma as a very aggressive type of endometrial cancer rather than a true sarcoma (Matsuzaki et al., 2021).

UCS makes up about 5% of womb cancers, and the number of cases has been slowly rising. It mostly affects women after the menopause, usually in their 60s and 70s. The most common first sign is bleeding from the vagina after the menopause.

Because it often spreads early, UCS is responsible for a much larger share of deaths from womb cancer than its small numbers would suggest (Toboni et al., 2025). Treatment usually combines surgery and chemotherapy, sometimes with radiotherapy.

1. Key facts at a glance

Feature Details
Type of cancer High-grade endometrial cancer with carcinoma and sarcoma components
Older name Malignant mixed Mullerian tumour (MMMT)
How common About 5 in 100 womb cancers
Typical age Mostly over 60; median about 65-70
Main symptom Bleeding after the menopause
Spread at diagnosis Often beyond the uterus, to lymph nodes, abdomen or lungs
Main treatment Hysterectomy and removal of ovaries and tubes, then chemotherapy
Standard chemotherapy Carboplatin and paclitaxel
Outlook Serious; about one-third alive at 5 years overall

2. Types of uterine carcinosarcoma

The two components

Component What it looks like Notes
Carcinoma Usually serous or endometrioid-type high-grade cancer; sometimes clear cell Drives spread to lymph nodes and the abdomen
Sarcoma Spindle cells and other mesenchymal cells Can dominate the tumour

Homologous and heterologous sarcoma

Type Meaning
Homologous The sarcoma looks like tissue normally found in the uterus, such as smooth muscle or stromal cells
Heterologous The sarcoma contains tissue not normally found in the uterus, such as cartilage, bone or skeletal muscle

Some studies suggest that a heterologous sarcoma or a sarcoma component making up more than half of the tumour is linked with a poorer outcome (Matsuzaki et al., 2021).

Carcinosarcoma can also arise in the ovary, fallopian tube, cervix or vagina. These are much rarer and are treated in similar ways.

How it differs from other womb cancers

Feature Common (endometrioid) womb cancer Carcinosarcoma
Grade Often low grade Always high grade
Spread at diagnosis Usually confined to the uterus Frequently beyond the uterus
Link with oestrogen Strong Weaker
Usual treatment Surgery alone for many Surgery plus chemotherapy for most
Outlook Generally good Considerably poorer

3. Causes and risk factors

The exact cause is not known. Many risk factors are shared with other womb cancers.

Risk factor Notes
Older age Most cases are after the menopause
Black ethnicity Black women are affected more often and tend to have poorer outcomes
Obesity Raises oestrogen levels after the menopause
Tamoxifen use Long-term use for breast cancer slightly increases the risk
Previous pelvic radiotherapy Linked with carcinosarcoma years later
Never having been pregnant Associated with womb cancers in general
Lynch syndrome An inherited condition that raises the risk of womb and bowel cancers; occasionally involved

Gene changes

Gene change Notes
TP53 Mutated in most tumours; similar to serous endometrial cancer
PIK3CA, PTEN, FBXW7, ARID1A Common additional changes
HER2 (ERBB2) Over-active in a proportion; a possible treatment target
Mismatch repair deficiency Present in a small minority; may respond to immunotherapy

Most of these changes occur only in the tumour. Testing for Lynch syndrome is offered if the tumour shows mismatch repair deficiency.

4. How does it look

Inside the womb

Feature Description
Shape A bulky, soft, polyp-like mass filling the womb cavity
Size Often large; may stretch the uterus
Position Can push down through the cervix and be visible at the vaginal opening
Surface Fleshy, with bleeding and areas of dead tissue
Cut surface Mixed appearance; sometimes gritty bone or glassy cartilage

On scans

Transvaginal ultrasound usually shows a thickened womb lining or a mass in the cavity. MRI of the pelvis shows how deeply the tumour has grown into the muscle wall and cervix. CT of the chest, abdomen and pelvis, or PET-CT, looks for spread to lymph nodes, the omentum (fatty apron in the abdomen), liver and lungs.

Under the microscope

Feature Description
Two cell types Malignant glands next to malignant spindle or other mesenchymal cells
Grade Both parts are high grade
Necrosis Often extensive
Lymphovascular invasion Common
Stains p53 (abnormal in most), mismatch repair proteins and HER2

5. Symptoms

Common symptoms

  • Bleeding from the vagina after the menopause
  • Heavy, irregular or prolonged bleeding in women nearing the menopause
  • Watery or bloodstained discharge, sometimes smelly
  • Pain or pressure in the pelvis
  • A lump felt or seen at the vaginal opening

Less common symptoms

Symptom What it may mean
Swollen abdomen Fluid or tumour deposits in the abdomen
Leg swelling Pressure on lymph nodes or veins
Cough or breathlessness Spread to the lungs
Tiredness and pale skin Anaemia from bleeding
Weight loss Advanced disease

When to seek medical advice

Any bleeding after the menopause should be checked by a doctor, even if it is a small amount or happens only once. Most causes are not cancer, but early assessment allows prompt diagnosis when it is.

6. Diagnosis

Test Purpose
Pelvic examination Checks the vagina, cervix and any visible mass
Transvaginal ultrasound Measures the womb lining
Endometrial biopsy A thin tube takes a sample from the womb lining
Hysteroscopy A camera looks inside the womb and samples abnormal areas
MRI pelvis Shows local extent
CT or PET-CT Checks for spread
Blood tests Blood count, kidney and liver function; CA-125 may be raised
Final pathology after surgery Confirms the diagnosis and stage

A biopsy may show only the carcinoma part, so the full diagnosis is sometimes made only after hysterectomy.

Staging

UCS is staged with the FIGO system used for endometrial cancer.

Stage What it means
Stage I Cancer confined to the body of the uterus
Stage II Spread into the cervix
Stage III Spread to the ovaries, tubes, vagina, pelvic tissues or lymph nodes
Stage IV Spread to the bladder, bowel, inside of the abdomen or distant organs

7. Treatment

Treatment is planned by a gynaecological oncology team.

Surgery

Procedure Notes
Total hysterectomy Removes the uterus and cervix
Bilateral salpingo-oophorectomy Removes both ovaries and fallopian tubes
Lymph node assessment Sentinel node biopsy or removal of pelvic and para-aortic nodes
Omentectomy and peritoneal biopsies Checks the abdomen for hidden spread
Debulking surgery Removes as much visible tumour as possible in advanced disease

Surgery may be done by keyhole (laparoscopic or robotic) or open methods, depending on the size of the uterus and the extent of disease.

Chemotherapy

Chemotherapy is recommended for most women, even with early-stage disease, because the risk of spread is high.

Regimen Notes
Carboplatin and paclitaxel Standard first choice; a large randomised trial showed it was at least as effective as paclitaxel with ifosfamide (Powell et al., 2022)
Paclitaxel and ifosfamide An older alternative with more confusion and bladder bleeding
Number of cycles Usually 6, given every 3 weeks

In that trial of 449 women with UCS, median survival was 37 months with carboplatin and paclitaxel compared with 29 months with paclitaxel and ifosfamide, and the cancer was controlled for longer (Powell et al., 2022).

Radiotherapy

Type When it may be used
Vaginal brachytherapy Internal radiotherapy to the top of the vagina to lower the risk of local recurrence
External beam pelvic radiotherapy For disease in the pelvis or lymph nodes, sometimes combined with chemotherapy
Palliative radiotherapy Controls bleeding or pain

Treatment of advanced or recurrent disease

Option Notes
Further chemotherapy Responses are less frequent after the first line
Immunotherapy Checkpoint inhibitors, alone or with chemotherapy, especially for mismatch repair-deficient tumours
Lenvatinib with pembrolizumab An option for some recurrent endometrial cancers
HER2-directed drugs For tumours with high HER2
Clinical trials Testing new targeted and immune treatments

Side effects

Treatment Possible side effects
Surgery Pain, wound problems, blood clots, early menopause symptoms if not already menopausal
Lymph node removal Leg swelling (lymphoedema)
Chemotherapy Tiredness, hair loss, low blood counts, infection risk, numbness in hands and feet
Radiotherapy Diarrhoea, bladder irritation, vaginal dryness and narrowing

What treatment involves day to day

Stage What to expect
Keyhole surgery Often 1-2 nights in hospital; back to light activity in 2-3 weeks
Open surgery Around 3-5 nights in hospital; recovery over 6 weeks
Chemotherapy A day-unit visit every 3 weeks for about 4-5 months
Brachytherapy A few short outpatient sessions

8. Outlook (prognosis)

UCS has a poorer outlook than most other womb cancers. Across all stages, about one-third of women are alive at 5 years, and this figure has changed little over several decades (Matsuzaki et al., 2021).

Factor Effect on outlook
Stage I disease Much better than average; many women are cured
Spread to lymph nodes or abdomen Higher risk of recurrence
Complete removal of visible tumour Better outcome
Sarcoma-dominant tumour Linked with poorer survival in some studies
Chemotherapy after surgery Lowers the risk of recurrence

When the cancer comes back, it often does so within 2 years, in the abdomen, pelvis or lungs.

9. Follow-up

Follow-up Purpose
Clinic visits every 3-4 months for 2-3 years Examination and review of symptoms
Every 6 months up to 5 years Continued monitoring
CT scans Often every 6 months in the first years, depending on stage
Vaginal examination Checks the top of the vagina
Support for late effects Lymphoedema, menopause symptoms, sexual health

10. Living with uterine carcinosarcoma

  • Report new bleeding, pain, swelling or cough promptly
  • Use vaginal dilators if advised after brachytherapy
  • Ask about lymphoedema care if your legs swell
  • Stay active within your limits to help with tiredness and strength
  • Discuss genetic testing if your tumour is mismatch repair-deficient
  • Seek emotional support from your team, specialist nurses or gynaecological cancer charities

11. Frequently asked questions

Question Answer
Is carcinosarcoma a sarcoma? Not really; it behaves as a high-grade endometrial cancer
Is it the same as MMMT? Yes, MMMT is the older name
Do I need chemotherapy if it is stage I? It is usually recommended because of the high risk of spread
Is it hereditary? Usually not, but a few cases are linked with Lynch syndrome
Can tamoxifen cause it? Long-term tamoxifen slightly raises the risk; its benefits for breast cancer usually outweigh this
Will I go into menopause? Yes, if you have not already, because the ovaries are removed
Does immunotherapy work? It helps some women, especially those with mismatch repair-deficient tumours
Can I keep my ovaries? Usually not, because the cancer can spread to them and most women are past the menopause

12. Questions to ask your care team

  • What stage is my cancer, and were the lymph nodes involved?
  • Was all visible tumour removed?
  • Which chemotherapy do you recommend, and for how many cycles?
  • Will I need radiotherapy?
  • Has my tumour been tested for mismatch repair, p53 and HER2?
  • Am I eligible for any clinical trials?

Resources

  1. Matsuzaki, S. et al. (2021) ‘Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity’, Gynecologic Oncology, 160(2), pp. 586-601.
  2. Pezzicoli, G. et al. (2021) ‘Uterine carcinosarcoma: an overview’, Critical Reviews in Oncology/Hematology, 163, 103369.
  3. Powell, M.A. et al. (2022) ‘Randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and ifosfamide in patients with carcinosarcoma of the uterus or ovary: an NRG Oncology trial’, Journal of Clinical Oncology, 40(9), pp. 968-977.
  4. Toboni, M. et al. (2025) ‘Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma’, International Journal of Gynecological Cancer, 35(3), 101672.
  5. National Cancer Institute (2026) Endometrial Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/uterine/hp/endometrial-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.